collection
MENU ▼
Read by QxMD icon Read
search

NOACs

shared collection
14 papers 25 to 100 followers New Oral Anticoagulant Agents
By Alessandro Iadanza Interventional Cardiologist at Siena University Hospital
https://www.readbyqxmd.com/read/27694263/how-long-should-we-wait-to-start-oral-anticoagulation-after-cardioembolic-stroke
#1
EDITORIAL
Brett Cucchiara
No abstract text is available yet for this article.
November 1, 2016: Neurology
https://www.readbyqxmd.com/read/27567465/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts-the-task-force-for-the-management-of-atrial-fibrillation-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the-european-heart
#2
Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, Anders Ahlsson, Dan Atar, Barbara Casadei, Manuel Castella, Hans-Christoph Diener, Hein Heidbuchel, Jeroen Hendriks, Gerhard Hindricks, Antonis S Manolis, Jonas Oldgren, Bogdan Alexandru Popescu, Ulrich Schotten, Bart Van Putte, Panagiotis Vardas
No abstract text is available yet for this article.
August 27, 2016: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/27560278/rhythm-control-in-atrial-fibrillation
#3
REVIEW
Jonathan P Piccini, Laurent Fauchier
Many patients with atrial fibrillation have substantial symptoms despite ventricular rate control and require restoration of sinus rhythm to improve their quality of life. Acute restoration (ie, cardioversion) and maintenance of sinus rhythm in patients with atrial fibrillation are referred to as rhythm control. The decision to pursue rhythm control is based on symptoms, the type of atrial fibrillation (paroxysmal, persistent, or long-standing persistent), patient comorbidities, general health status, and anticoagulation status...
August 20, 2016: Lancet
https://www.readbyqxmd.com/read/27567408/2016-esc-guidelines-for-the-management-of-atrial-fibrillation-developed-in-collaboration-with-eacts-the-task-force-for-the-management-of-atrial-fibrillation-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the-european-heart
#4
Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, Anders Ahlsson, Dan Atar, Barbara Casadei, Manuel Castella, Hans-Christoph Diener, Hein Heidbuchel, Jeroen Hendriks, Gerhard Hindricks, Antonis S Manolis, Jonas Oldgren, Bogdan Alexandru Popescu, Ulrich Schotten, Bart Van Putte, Panagiotis Vardas
No abstract text is available yet for this article.
August 27, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27436881/management-of-bleeding-with-non-vitamin-k-antagonist-oral-anticoagulants-in-the-era-of-specific-reversal-agents
#5
Christian T Ruff, Robert P Giugliano, Elliott M Antman
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists. There are now 4 new non-vitamin K antagonist oral anticoagulants (NOACs) that are attractive alternatives to vitamin K antagonists. Despite similar or lower rates of serious bleeding with NOACs in comparison with warfarin, there is a pressing need for strategies to manage bleeding when it does occur with NOACs and to reverse the pharmacological effect of these agents if needed...
July 19, 2016: Circulation
https://www.readbyqxmd.com/read/26848150/choosing-a-particular-oral-anticoagulant-and-dose-for-stroke-prevention-in-individual-patients-with-non-valvular-atrial-fibrillation-part-2
#6
Hans-Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, Günter Breithardt, John Eikelboom, Michael D Ezekowitz, Christopher B Granger, Jonathan L Halperin, Stefan H Hohnloser, Elaine M Hylek, Paulus Kirchhof, Deirdre A Lane, Freek W A Verheugt, Roland Veltkamp, Gregory Y H Lip
The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or transient ischaemic attack (TIA), (viii) patients with acute stroke requiring thrombolysis or thrombectomy, (ix) those initiating or restarting OAC treatment after stroke or TIA, (x) those with renal impairment on dialysis, (xi) the elderly, (xii) those at high risk of gastrointestinal bleeding, and (xiii) those with hypertension...
February 4, 2016: European Heart Journal
https://www.readbyqxmd.com/read/26848149/choosing-a-particular-oral-anticoagulant-and-dose-for-stroke-prevention-in-individual-patients-with-non-valvular-atrial-fibrillation-part-1
#7
Hans-Christoph Diener, James Aisenberg, Jack Ansell, Dan Atar, Günter Breithardt, John Eikelboom, Michael D Ezekowitz, Christopher B Granger, Jonathan L Halperin, Stefan H Hohnloser, Elaine M Hylek, Paulus Kirchhof, Deirdre A Lane, Freek W A Verheugt, Roland Veltkamp, Gregory Y H Lip
Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs...
February 4, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27282612/updated-european-heart-rhythm-association-practical-guide-on-the-use-of-non-vitamin-k-antagonist-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation-executive-summary
#8
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A John Camm, Paulus Kirchhof
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P...
June 9, 2016: European Heart Journal
https://www.readbyqxmd.com/read/26946415/anticoagulation-in-coronary-intervention
#9
Uwe Zeymer, Sunil V Rao, Gilles Montalescot
Percutaneous coronary intervention (PCI) induces thrombin generation and is associated with the risk of acute, subacute, or long-term ischaemic events. Therefore, intravenous anticoagulation is recommended to minimize thrombotic complications. The intensity and duration of anticoagulation needed are dependent on the clinical presentation (elective PCI for stable coronary artery disease, PCI for non-ST elevation acute coronary syndromes, or primary PCI for ST-segment elevation myocardial infarction) and procedural features...
March 5, 2016: European Heart Journal
https://www.readbyqxmd.com/read/26713281/monitoring-anticoagulant-therapy-with-new-oral-agents
#10
REVIEW
Allan Ramos-Esquivel
Thromboembolic disease is a major leading cause of mortality and morbidity in industrialized countries. Currently, the management of these patients is challenging due to the availability of new drugs with proven efficacy and security compared to traditional oral vitamin K antagonists. These compounds are characterized by a predictable pharmacokinetic profile for which blood monitoring is not routinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety...
December 26, 2015: World Journal of Methodology
https://www.readbyqxmd.com/read/25421049/cardiology-patient-page-warfarin-versus-novel-oral-anticoagulants-how-to-choose
#11
REVIEW
Rishi K Wadhera, Cori E Russell, Gregory Piazza
No abstract text is available yet for this article.
November 25, 2014: Circulation
https://www.readbyqxmd.com/read/24845012/-rivaroxaban-dabigatran-and-apixaban-new-anticoagulants-in-operative-urology
#12
A John, M S Michel
The periprocedural management of patients receiving long-term oral anticoagulant therapy is a common but complex clinical problem. It is well established that maintaining oral anticoagulation is associated with an increased risk of bleeding in the periprocedural period while discontinuing anticoagulant therapy postoperatively leads to an elevated risk for thromboembolic events, especially in high risk patients. Nowadays there is growing evidence to maintain antiplatelet therapy with acetylsalicylic acid (ASS, Aspirin®) perioperatively in a setting of secondary prophylaxis...
June 2014: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/15191946/new-anticoagulants
#13
REVIEW
Jack Hirsh, Martin O'Donnell, Jeffrey I Weitz
Anticoagulants are pivotal agents for prevention and treatment of thromboembolic disorders. Limitations of existing anticoagulants, vitamin K antagonist and heparins, have led to the development of newer anticoagulant therapies. These anticoagulants have been designed to target specific coagulation enzymes or steps in the coagulation pathway. New anticoagulants that are under evaluation in clinical trials include: (1) inhibitors of the factor VIIa/tissue factor pathway; (2) factor Xa inhibitors, both indirect and direct; (3) activated protein C and soluble thrombomodulin; and (4) direct thrombin inhibitors...
January 15, 2005: Blood
https://www.readbyqxmd.com/read/25154388/management-of-antithrombotic-therapy-in-atrial-fibrillation-patients-presenting-with-acute-coronary-syndrome-and-or-undergoing-percutaneous-coronary-or-valve-interventions-a-joint-consensus-document-of-the-european-society-of-cardiology-working-group-on-thrombosis
#14
Gregory Y H Lip, Stephan Windecker, Kurt Huber, Paulus Kirchhof, Francisco Marin, Jurriën M Ten Berg, Karl Georg Haeusler, Giuseppe Boriani, Davide Capodanno, Martine Gilard, Uwe Zeymer, Deirdre Lane, Robert F Storey, Hector Bueno, Jean-Philippe Collet, Laurent Fauchier, Sigrun Halvorsen, Maddalena Lettino, Joao Morais, Christian Mueller, Tatjana S Potpara, Lars Hvilsted Rasmussen, Andrea Rubboli, Juan Tamargo, Marco Valgimigli, Jose L Zamorano
No abstract text is available yet for this article.
December 1, 2014: European Heart Journal
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"